- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05243303
Augmenting Standard-of-care Treatment of Plaque Psoriasis by Neuromodulation
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
An estimated 20% of psoriasis patients experience treatment failure. Afferent vagal nerve fibers that are part of the anti-inflammatory reflex sense inflammation, such as psoriatic skin lesions. The investigators' pilot data show that transcutaneous auricular vagus nerve stimulation (taVNS) activates afferent nerve fibers within the auricular branch of the vagus nerve to trigger anti-inflammatory reflex responses in healthy individuals. However, it is unknown if taVNS improves plaque psoriasis through the anti-inflammatory reflex. The lack of studies on taVNS in plaque psoriasis constitutes a missed opportunity to reduce treatment failures.
The long-term goal of this research is to establish a neuromodulatory approach to activate the anti-inflammatory reflex in patients with plaque psoriasis to lessen treatment failures. The objective of this study is to test the hypothesis that taVNS elicits anti-inflammatory reflex responses and reduces the severity of plaque psoriasis.
In a single-blinded randomized controlled clinical trial, participants will self-administer taVNS or sham-taVNS (control) daily for a duration of 3 months, while continuing their standard-of-care treatment. At baseline, 7 days, and 1, 2, and 3 months, clinical , autonomic, and inflammatory responses will be assessed.
At the conclusion of this study, the investigators expect to demonstrate anti-inflammatory reflex responses to taVNS and reduced severity of plaque psoriasis. These outcomes are expected to have important positive impact, because they are anticipated to reduce treatment failures in patients with plaque psoriasis.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Harald M Stauss, MD, PhD
- Phone Number: 575-674-2327
- Email: hstauss@burrell.edu
Study Locations
-
-
New Mexico
-
Las Cruces, New Mexico, United States, 88001
- Recruiting
- Burrell College of Osteopathic Medicine
-
Contact:
- Harald M Stauss, MD, PhD
- Phone Number: 575-674-2327
- Email: hstauss@bcomnm.org
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- 18 years or older
- Plaque psoriasis diagnosed by a dermatologist
Exclusion Criteria:
- pregnancy
- vestibulocochlear neuronitis or nerve damage
- cardiac arrhythmia
- epilepsy
- anticipated change in medication during the 3-month study period
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Active taVNS
These patients will self-administer transcutaneous auricular vagus nerve stimulation (taVNS).
|
A bipolar clip electrode is placed at the cymba conchae of the ear.
Through this bipolar clip electrode, afferent nerve fibers within the auricular branch of the vagus nerve will be stimulated.
Subjects self-administer the stimulation on a daily basis for 3 months.
Other Names:
|
Sham Comparator: Sham taVNS
These patients will self-administer a sham procedure mimicking the active taVNS procedure.
|
A bipolar clip electrode is placed at the cymba conchae of the ear.
However, active stimulation of the afferent nerve fibers within the auricular branch of the vagus nerve will not occur, because the electrode wire is electrically interrupted.
Subjects self-administer the sham taVNS on a daily basis for 3 months.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Psoriasis Area and Severity Index from Baseline at 1 Week
Time Frame: After 1 week of treatment.
|
Clinical assessment of the severity of plaque psoriasis
|
After 1 week of treatment.
|
Change in Psoriasis Area and Severity Index from Baseline at 1 Month
Time Frame: After 1 month of treatment.
|
Clinical assessment of the severity of plaque psoriasis
|
After 1 month of treatment.
|
Change in Psoriasis Area and Severity Index from Baseline at 2 Months
Time Frame: After 2 months of treatment.
|
Clinical assessment of the severity of plaque psoriasis
|
After 2 months of treatment.
|
Change in Psoriasis Area and Severity Index from Baseline at 3 Months
Time Frame: After 3 months of treatment.
|
Clinical assessment of the severity of plaque psoriasis
|
After 3 months of treatment.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Heart Rate Variability from Baseline at 1 Week
Time Frame: After 1 week of treatment.
|
Heart rate variability will be determined from ECG recordings
|
After 1 week of treatment.
|
Change in Heart Rate Variability from Baseline at 1 Month
Time Frame: After 1 month of treatment.
|
Heart rate variability will be determined from ECG recordings
|
After 1 month of treatment.
|
Change in Heart Rate Variability from Baseline at 2 Months
Time Frame: After 2 months of treatment.
|
Heart rate variability will be determined from ECG recordings
|
After 2 months of treatment.
|
Change in Heart Rate Variability from Baseline at 3 Months
Time Frame: After 3 months of treatment.
|
Heart rate variability will be determined from ECG recordings
|
After 3 months of treatment.
|
Change in Plasma Cytokine Levels from Baseline at 1 Week
Time Frame: After 1 week of treatment.
|
Plasma concentrations (pg/mL) for 8 different cytokines (GM CSF, IFN-γ, IL-2, IL-4, IL-6, IL-8, IL-10, and TNF-α) will be determined from blood samples.
|
After 1 week of treatment.
|
Change in Plasma Cytokine Levels from Baseline at 1 Month
Time Frame: After 1 month of treatment.
|
Plasma concentrations (pg/mL) for 8 different cytokines (GM CSF, IFN-γ, IL-2, IL-4, IL-6, IL-8, IL-10, and TNF-α) will be determined from blood samples.
|
After 1 month of treatment.
|
Change in Plasma Cytokine Levels from Baseline at 2 Months
Time Frame: After 2 months of treatment.
|
Plasma concentrations (pg/mL) for 8 different cytokines (GM CSF, IFN-γ, IL-2, IL-4, IL-6, IL-8, IL-10, and TNF-α) will be determined from blood samples.
|
After 2 months of treatment.
|
Change in Plasma Cytokine Levels from Baseline at 3 Months
Time Frame: After 3 months of treatment.
|
Plasma concentrations (pg/mL) for 8 different cytokines (GM CSF, IFN-γ, IL-2, IL-4, IL-6, IL-8, IL-10, and TNF-α) will be determined from blood samples.
|
After 3 months of treatment.
|
Change from baseline in cytokine release from cultured leukocytes at 1 week
Time Frame: After 1 week of treatment.
|
Cytokine concentrations (pg/mL) for 8 different cytokines (GM CSF, IFN-γ, IL-2, IL-4, IL-6, IL-8, IL-10, and TNF-α) will be measured in supernatant from LPS-stimulated leukocyte cultures.
|
After 1 week of treatment.
|
Change from baseline in cytokine release from cultured leukocytes at 1 month
Time Frame: After 1 month of treatment.
|
Cytokine concentrations (pg/mL) for 8 different cytokines (GM CSF, IFN-γ, IL-2, IL-4, IL-6, IL-8, IL-10, and TNF-α) will be measured in supernatant from LPS-stimulated leukocyte cultures.
|
After 1 month of treatment.
|
Change from baseline in cytokine release from cultured leukocytes at 2 months
Time Frame: After 2 months of treatment.
|
Cytokine concentrations (pg/mL) for 8 different cytokines (GM CSF, IFN-γ, IL-2, IL-4, IL-6, IL-8, IL-10, and TNF-α) will be measured in supernatant from LPS-stimulated leukocyte cultures.
|
After 2 months of treatment.
|
Change from baseline in cytokine release from cultured leukocytes at 3 months
Time Frame: After 3 months of treatment.
|
Cytokine concentrations (pg/mL) for 8 different cytokines (GM CSF, IFN-γ, IL-2, IL-4, IL-6, IL-8, IL-10, and TNF-α) will be measured in supernatant from LPS-stimulated leukocyte cultures.
|
After 3 months of treatment.
|
Collaborators and Investigators
Investigators
- Principal Investigator: Harald M Stauss, MD, PhD, Burrell College of Osteopathic Medicine
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0090_2021
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Psoriasis Vulgaris
-
LEO PharmaCompletedPlaque Psoriasis | Psoriasis VulgarisGermany
-
SoligenixRecruitingPsoriasis | Plaque Psoriasis | Psoriasis VulgarisUnited States
-
LEO PharmaTerminatedPsoriasis | Plaque Psoriasis | Psoriasis VulgarisBelgium, Germany, Italy, Spain, Denmark, Austria, France, Greece, Switzerland, United Kingdom, Netherlands, Sweden
-
PRCL Research Inc.CompletedPlaque Psoriasis | Psoriasis VulgarisCanada, Slovakia, Ukraine
-
University Hospital, GhentBelgium Health Care Knowledge CentreNot yet recruiting
-
Chinese University of Hong KongNot yet recruitingPsoriasis Vulgaris
-
University Hospital, GhentRecruitingPsoriasis VulgarisBelgium
-
University Hospital, GhentRecruitingPsoriasis VulgarisBelgium
-
University of California, San FranciscoNovartis Pharmaceuticals; National Psoriasis FoundationRecruitingPsoriasis VulgarisUnited States
-
Centre for Human Drug Research, NetherlandsJanssen PharmaceuticalsRecruiting
Clinical Trials on Active taVNS
-
University of FloridaNot yet recruiting
-
University of LiegeRecruitingMinimally Conscious State | Vegetative State | Consciousness DisorderBelgium
-
Medical University of South CarolinaNational Institute on Drug Abuse (NIDA); National Institutes of Health (NIH)Completed
-
Federal University of São PauloUnknown
-
Burrell College of Osteopathic MedicineNot yet recruitingAtrial Fibrillation, PersistentUnited States
-
Possover International Medical Center AGNot yet recruitingCentral Nervous System Diseases | Nervous System Diseases | Movement Disorders | Trauma, Nervous System | Spinal Cord Diseases | Spinal Cord Injuries
-
Medical University of South CarolinaCompleted
-
Medical University of South CarolinaNational Institutes of Health (NIH); National Institute of General Medical...Completed
-
University of HartfordNot yet recruitingHealthy VolunteersUnited States
-
Qiuyou XieBrainClos Co., LTD.; Zhuhai Fudan Innovation InstituteRecruitingStroke | Upper Extremity DysfunctionChina